rylaze

Generic: asparaginase erwinia chrysanthemi (recombinant)-rywn·Code: JZP458

rylaze: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
Jazz Pharmaceuticals plc (JAZZ)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma ((JAZZ)

Frequently asked questions

Who is developing rylaze?

rylaze is being developed by Jazz Pharmaceuticals plc.

What is rylaze's latest FDA decision?

The most recent tracked FDA decision for rylaze is Approval for 1 INDICATIONS AND USAGE RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. RYLAZE is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (, dated June 30, 2021.

Get deeper analysis on rylaze

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    rylaze — Drug Pipeline, Trials & FDA Status | BioSniper